South Korea · Delayed Price · Currency is KRW BioNote Statistics
Total Valuation
BioNote has a market cap or net worth of KRW 482.68 billion. The enterprise value is 122.67 billion.
| Market Cap | 482.68B |
| Enterprise Value | 122.67B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
BioNote has 101.19 million shares outstanding. The number of shares has decreased by -0.54% in one year.
| Current Share Class | 101.19M |
| Shares Outstanding | 101.19M |
| Shares Change (YoY) | -0.54% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 59.12% |
| Owned by Institutions (%) | 0.26% |
| Float | 13.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.94 |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.31 |
| P/FCF Ratio | 26.12 |
| P/OCF Ratio | 20.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.37, with an EV/FCF ratio of 6.64.
| EV / Earnings | -2.44 |
| EV / Sales | 1.00 |
| EV / EBITDA | 4.37 |
| EV / EBIT | 6.64 |
| EV / FCF | 6.64 |
Financial Position
The company has a current ratio of 10.15, with a Debt / Equity ratio of 0.00.
| Current Ratio | 10.15 |
| Quick Ratio | 9.41 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | 0.18 |
| Interest Coverage | 76.62 |
Financial Efficiency
Return on equity (ROE) is -3.18% and return on invested capital (ROIC) is 1.57%.
| Return on Equity (ROE) | -3.18% |
| Return on Assets (ROA) | 0.70% |
| Return on Invested Capital (ROIC) | 1.57% |
| Return on Capital Employed (ROCE) | 1.18% |
| Weighted Average Cost of Capital (WACC) | 8.07% |
| Revenue Per Employee | 410.89M |
| Profits Per Employee | -168.54M |
| Employee Count | 298 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 1.98 |
Taxes
| Income Tax | -1.80B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.47% in the last 52 weeks. The beta is 0.70, so BioNote's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -6.47% |
| 50-Day Moving Average | 5,078.60 |
| 200-Day Moving Average | 5,476.05 |
| Relative Strength Index (RSI) | 35.93 |
| Average Volume (20 Days) | 98,367 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioNote had revenue of KRW 122.44 billion and -50.23 billion in losses. Loss per share was -496.95.
| Revenue | 122.44B |
| Gross Profit | 69.60B |
| Operating Income | 18.47B |
| Pretax Income | -52.03B |
| Net Income | -50.23B |
| EBITDA | 28.05B |
| EBIT | 18.47B |
| Loss Per Share | -496.95 |
Balance Sheet
The company has 363.35 billion in cash and 3.33 billion in debt, with a net cash position of 360.02 billion or 3,557.78 per share.
| Cash & Cash Equivalents | 363.35B |
| Total Debt | 3.33B |
| Net Cash | 360.02B |
| Net Cash Per Share | 3,557.78 |
| Equity (Book Value) | 1.54T |
| Book Value Per Share | 15,328.27 |
| Working Capital | 399.85B |
Cash Flow
In the last 12 months, operating cash flow was 23.88 billion and capital expenditures -5.40 billion, giving a free cash flow of 18.48 billion.
| Operating Cash Flow | 23.88B |
| Capital Expenditures | -5.40B |
| Depreciation & Amortization | 9.58B |
| Net Borrowing | -1.34B |
| Free Cash Flow | 18.48B |
| FCF Per Share | 182.64 |
Margins
Gross margin is 56.84%, with operating and profit margins of 15.09% and -41.02%.
| Gross Margin | 56.84% |
| Operating Margin | 15.09% |
| Pretax Margin | -42.49% |
| Profit Margin | -41.02% |
| EBITDA Margin | 22.91% |
| EBIT Margin | 15.09% |
| FCF Margin | 15.09% |
Dividends & Yields
This stock pays an annual dividend of 200.00, which amounts to a dividend yield of 4.19%.
| Dividend Per Share | 200.00 |
| Dividend Yield | 4.19% |
| Dividend Growth (YoY) | 14.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.54% |
| Shareholder Yield | 4.75% |
| Earnings Yield | -10.41% |
| FCF Yield | 3.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNote has an Altman Z-Score of 6.4 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.4 |
| Piotroski F-Score | 5 |